Current Biologics Names Chief Executive
Post Date: September 20, 2022 | Publish Date:
Startup firm is focused on cell and gene therapy manufacturing
The board of Current Biologics has selected Tom Hochuli as chief executive officer of the startup company, which is focused on providing cell and gene therapy manufacturing and development services to the biotechnology and pharmaceutical industries.
Current Biologics was established as a joint venture of Cincinnati Children’s and CTI Clinical Trial & Consulting Services.
“Tom Hochuli brings more than 30 years of leadership experience in the biologics, pharmaceutical, medical device, and consumer products industries,” says Steve Davis, MD, president and CEO of Cincinnati Children’s. “His expertise will guide Current Biologics as the company recruits talent and builds a state-of-the-art current Good Manufacturing Practice facility capable of producing multiple vectors for cell and gene therapy research. With Tom’s leadership, Current Biologics will ensure that our patients – and others around the world – have access to the most innovative and effective medical therapies.”
For the last two years, Hochuli has been CEO of Vibalogics Holdings LLC, a virotherapy process development and manufacturing organization near Boston. He previously had a leadership role with the Lonza cell and gene therapy manufacturing facility in Houston.
Cell-based therapies involve the administration of live cells to a patient to treat or cure a disease by replenishing or replacing damaged/dysfunctional cells. Gene therapy involves the introduction, replacement, removal, or change in the content of an individual’s genetic code to treat or cure a disease.
The Cincinnati Children’s Translational Core Laboratory has been a leader in the development, testing and cGMP manufacturing of biological therapeutics for early phase clinical trials for more than 15 years.
“Current Biologics will support Cincinnati Children’s efforts as one of the world’s leading medical centers committed to scientific research and innovation,” Hochuli says. “I’m pleased to have a role in helping the medical center expand the services of its Translational Core Laboratory.”
